robust-formulation-development-for-clinical-trials
The journey from lab to clinical trials is full of roadblocks. Getting drug product formulation right is critical to avoid costly delays and ensure success. Learn how robust formulation development provides a solid foundation for your clinical program.
Menu
Getting Formulation Right for the Clinic: A Practical Guide
1. Current Situation
2. Typical Market Trends
3. Current Challenges and How They Are Solved
4. How Leukocare Can Support These Challenges
5. Value Provided to Customers
6. FAQ
Getting Formulation Right for the Clinic: A Practical Guide
Moving a promising molecule into clinical trials is a major milestone. But the path from lab discovery to first-in-human studies is full of potential roadblocks. One of the most critical elements for a smooth journey is the drug product formulation. Get it right, and you build a solid foundation for the entire clinical program. Get it wrong, and you can face costly delays, inconclusive results, or even complete failure.
For leaders in CMC and Drug Product Development, the pressure is immense. You need to move fast, use minimal material, and deliver a stable, effective product that satisfies regulators and investors.
1. Current Situation
Today’s drug pipelines are filled with increasingly complex molecules. Monoclonal antibodies, antibody-drug conjugates (ADCs), and advanced therapies like viral vectors and RNA-based medicines present unique stability challenges that older, simpler molecules did not. These biologics are large and sensitive to their environment; any change in their structure can lead to a loss of efficacy or, worse, trigger an immune response in patients. [1, 2]
The pressure to accelerate timelines has never been greater. [1, 2] For a virtual or small biotech, the speed at which you can generate clinical data is directly tied to funding and survival. This environment leaves little room for error.
2. Typical Market Trends
The biopharmaceutical industry is adapting to these pressures. Several key trends are shaping how companies approach formulation development:
Rise of Subcutaneous Delivery: To improve the patient experience and reduce healthcare costs, many therapies are moving from intravenous (IV) infusion to subcutaneous (at-home) injection. This requires highly concentrated formulations (>100 mg/mL), which introduces significant challenges like high viscosity and increased potential for protein aggregation. [3, 4]
Outsourcing is the Norm: Virtual and small biotechs rely almost entirely on outsourcing partners like contract development and manufacturing organizations (CDMOs). [5] Even larger companies are outsourcing specialized work to access specific technologies and manage internal capacity. [7, 8] The global market for formulation development outsourcing was valued at $21.1 billion in 2021 and is projected to grow substantially.
Data-Driven Development: Companies are increasingly using predictive modeling, artificial intelligence (AI), and high-throughput screening tools to make formulation development faster and more efficient. [9] These technologies help identify optimal conditions with less time and material. [10, 11, 30]
Focus on Phase-Appropriateness: There is a growing understanding that the formulation for a Phase 1 study doesn't need to be the final commercial formulation. [11, 12, 20] A phase-appropriate strategy focuses on developing a safe and stable product that meets the needs of early clinical trials, saving time and resources. [13]
3. Current Challenges and How They Are Solved
Directors of CMC and Drug Product Development face a common set of hurdles. [15, 16] Here’s a look at the biggest challenges and how they are typically addressed.
Challenge: The Speed vs. Stability Dilemma
Everyone wants to reach the IND filing as fast as possible, but rushing formulation can lead to a product that degrades on the shelf. This could force a costly reformulation and bridging studies later on. Stability data is a critical component of any IND application. [17, 19]How it's solved: A phase-appropriate approach is key. The goal for Phase 1 is a simple, stable formulation that ensures patient safety and delivers the drug effectively. While complete, long-term stability data isn't expected for Phase 1 studies, the formulation must be stable for the trial's duration. [16] This allows development to proceed quickly while more complex work on a final formulation continues in parallel. [17, 19] You can learn more about Navigating the Formulation Maze: Phase-Appropriate Formulation for Clinical bsAbs in our related article. [13]
Challenge: Limited Drug Substance
In early development, the active pharmaceutical ingredient (API) is incredibly precious and expensive. There often isn't enough material to conduct extensive formulation screening using traditional methods.How it's solved: Modern formulation labs use high-throughput, low-volume analytical methods to screen many conditions at once with minimal sample. They also employ predictive modeling and AI-driven platforms that use existing data to forecast which combinations of excipients will likely work best, narrowing the field of candidates for physical testing. [5] This data-first approach maximizes learning from every milligram of material. [11, 12, 20, 30] For more on this, see our article on Beyond the Blueprint: AI-Guided Formulation Design for Bispecifics.
Challenge: Increasing Molecular Complexity
New modalities like cell and gene therapies, or advanced biologics such as bispecific antibodies, don't fit into standard formulation playbooks. For example, the materials used in Advanced Therapy Medicinal Products (ATMPs) can have high variability, and formulating them requires specialized expertise. [21, 22]How it's solved: Success requires a partner with deep scientific understanding of specific molecular classes. This involves looking beyond standard excipients and considering unique stabilizers. It also means having analytics that can detect subtle changes specific to that molecule type. A detailed guide on Formulation Development for Complex Biologic Drugs can provide further information.
Challenge: Finding the Right Outsourcing Partner
Choosing a CDMO or specialized formulation partner is a critical decision. Many teams have had poor experiences with partners who are too academic, not proactive, or simply act as a "pair of hands" instead of a strategic collaborator. [23]How it's solved: The best partnerships are collaborative. Look for a team that challenges assumptions, offers proactive solutions, and communicates clearly. They should function as an extension of your own team, providing strategic input, not just executing orders. A good partner helps you build a strong CMC story for investors and regulators. [23]
4. How Leukocare Can Support These Challenges
At Leukocare, we understand these challenges because we help companies navigate them every day. Our approach is built around providing strategic, data-driven formulation solutions.
We use our Smart Formulation platform, which combines proprietary excipients with AI-based predictive modeling. This allows us to quickly identify promising formulation candidates and create a focused, efficient development plan, even with limited material. Our process helps de-risk development and supports a rapid bsAb formulation development timeline.
We work as a collaborative partner, not just a service provider. Our team of experienced CMC professionals provides proactive, solution-oriented guidance. We pride ourselves on clear communication and delivering structured, dependable results that are aligned with investor and regulatory expectations. For teams working on the next wave of therapies, our deep know-how in areas like viral vectors and complex proteins offers a path forward for even the most difficult-to-formulate molecules.
5. Value Provided to Customers
Working with a dedicated formulation partner provides tangible value beyond the lab bench. The goal is to create a clear and efficient path to the clinic and beyond.
De-risking Your Asset: A well-developed formulation built on solid data reduces the risk of costly surprises down the road, such as stability failures or the need for reformulation.
Accelerating Timelines: By using predictive tools and phase-appropriate strategies, the timeline to a stable, clinic-ready formulation can be significantly shortened.
Building a Strong CMC Package: A data-driven approach generates the robust information needed for a successful IND filing and provides a strong CMC story for discussions with investors. [24]
Saving Precious Material: High-throughput and in-silico methods ensure that you get the most information from a minimal amount of your valuable drug substance. [25]
Freeing Up Your Team: Partnering with a specialist allows your internal team to focus on core activities like overall strategy and pipeline management, confident that the formulation is in expert hands. Finding Finding a Simpler Path: Optimized Formulation Services for Biologic Drugs can make a significant difference.
6. FAQ
Q: How early should we start thinking about formulation?
A: As soon as you have a lead candidate. Early pre-formulation studies assess the inherent properties of your molecule and identify potential challenges. This foundational data informs the entire development strategy. [26]
Q: Is it okay to use a simple formulation for Phase 1 and optimize it later?
A: Yes, this is a standard and recommended phase-appropriate strategy. The goal for early trials is to establish safety and proof-of-concept with a stable, functional formulation. [27] This allows you to move into the clinic faster while continuing to develop the final commercial formulation in parallel.
Q: We have a novel molecule (e.g., a viral vector). How can we find a partner with the right experience?
A: Look for a partner who can demonstrate specific expertise with your modality. Ask for case studies or examples of how they have handled similar molecules. A true specialist will understand the unique stability challenges and analytical methods required for advanced therapies like those discussed in ATMP Formulation Development.
Q: What does an "AI-driven" or "predictive" approach to formulation actually mean? [28, 29]
A: It means using computational tools and algorithms to analyze data from thousands of previous experiments to predict which excipients and conditions are most likely to stabilize a specific molecule. This reduces trial-and-error lab work, saving significant time and material by focusing experiments on the most promising candidates. [11, 30]
Literature
High Concentration Biologic Formulations: Challenges and Solutions. (2017). American Pharmaceutical Review.
Manufacturing Challenges With High Concentration Biologics. Bioprocess Online.
Manufacturing challenges with high concentration biologics. Cytiva.
Formulation Development Strategies for Biologics Product. Pharma Lesson.
Overcoming Challenges Associated with Biologic Drug Formulation & Development. (2019). West Pharmaceutical Services.
Biologics Formulation Challenges. (2022). Ascendia Pharmaceutical Solutions.
Evaluation of predictive computational modelling in biologic formulation development. (2017). MIT DSpace.
Overcoming Challenges to High-Concentration Formulation Development. (2025). Samsung Biologics.
Predictive Screening Tools Used in High-Concentration Protein Formulation Development. (2017). Journal of Pharmaceutical Sciences.
Challenges in Formulating Biologics. (2019). IDBS.
What are the common challenges in biologic drug development? (2025). Patsnap.
Predictive Modeling for Formulation Development: Coformers, Cocrystals, Complexes. (2023). Pharmaceutical Technology.
Overcoming Biologic Drug Formulation Hurdles. (2021). Pharmaceutical Technology.
Key trends and technologies in drug delivery for 2025 and beyond. (2025). Pharma Manufacturing.
Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product. Drug Development & Delivery.
Preparing an IND Application: 5 Best Practices from the Field. (2025). The FDA Group.
Outsourcing Formulation Services for Biologics. (2023). BioPharm International.
Predictive modeling for solubility and bioavailability enhancement. (2024). Patheon.
A computational procedure for predicting excipient effects on protein-protein affinities. (2021). bioRxiv.
Pharmaceutical Formulation Development: A Guide to Outsourcing Formulation Development. PharmaSource.
A Guide To Pharmaceutical & Biotech Development & Manufacturing Outsourcing. Life Science Leader.
Embracing A New Standard For Regulatory Development: 3 Key Considerations For Phase Appropriate GMPs. (2020). Bioprocess Online.
Outsourcing Formulation Development & Manufacturing: Going Beyond the Science to Become True Partners. Drug Development & Delivery.
Drug Formulation Market Growth Forecast 2025-2035. World Pharma Today.
Stability Studies and Testing of Pharmaceuticals - An Overview. LCGC International.
Transitioning from Formulation Development to Phase 1 Clinical Trials. SGS.
The Importance of Formulation Development in Successful Drug Development. Vici.
Pharmaceutical Formulation Market Trends 2025 Insights and Best Practices for Global Buyers. USSF.
The Role of Immunogenicity in Biologic Drug Development. (2024). Sword Bio.
Phase-Appropriate Formulation and Process Design. (2016). Pharmaceutical Technology.
10 Essential Considerations for Successful Clinical Development of ATMPs. Scendea.
Highly Innovative Medicines: Advanced Therapy Medicinal Products (ATMPs) - Part 2. (2024). GMP-Publishing.
Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. Taylor & Francis Online.
Formulation, Stability, and Delivery Conference. (2025). The Bioprocessing Summit.
Developing Formulations for Phase 1 Clinical Trials. BioPharma Services.
Road Map for Drug Product Development and Manufacturing of Biologics. (2024). YouTube.
Bio/Pharma Outlook 2025: The Year Ahead. (2025). DCAT Value Chain Insights.
Drug Formulation Development and Clinical Trials: A Quick Guide for Biotech Companies. (2020). Sofpromed.
Formulation and manufacturability of biologics. (2025). ResearchGate.
Maximizing Drug Formulation for First-in-Human Trials. Altasciences.
Early Development GMPs for Stability (Part IV). (2012). Pharmaceutical Technology.
Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults. PubMed Central.
Guidelines relevant for advanced therapy medicinal products. European Medicines Agency.
Regulatory, clinical and logistics challenges of Advanced Therapy Medicinal Products (ATMPs) in clinical research. (2017). European Pharmaceutical Review.
Stability Requirements In The 505(b)(2) Space: Why, What, When, How. (2017). Premier Consulting.
Advanced Therapy Medicinal Products (ATMPs) and their groundbreaking potential. TRANSFORM Alliance.
IND Applications for Clinical Investigations: Chemistry, Manufacturing, and Control (CMC) Information. (2022). FDA.
